MedPath

Kiniksa Pharmaceuticals International

🇧🇲Bermuda
Ownership
-
Employees
297
Market Cap
$1.9B
Website
Introduction

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Clinical Trials

13

Active:9
Completed:4

Trial Phases

2 Phases

Phase 1:10
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (76.9%)
Phase 2
3 (23.1%)

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: Placebo
First Posted Date
2022-01-20
Last Posted Date
2025-07-22
Lead Sponsor
Kiniksa Pharmaceuticals, Ltd.
Target Recruit Count
145
Registration Number
NCT05198310
Locations
🇺🇸

Carewell Arthritis Center, Apple Valley, California, United States

🇺🇸

Medvin Clinical Research, Whittier, California, United States

🇺🇸

Inland Rheumatology Clinical Trials, Upland, California, United States

and more 38 locations

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Other: Matching Placebo
First Posted Date
2020-08-04
Last Posted Date
2021-05-04
Lead Sponsor
Kiniksa Pharmaceuticals, Ltd.
Target Recruit Count
52
Registration Number
NCT04497662
Locations
🇺🇸

PPD Clinic, Austin, Texas, United States

🇦🇺

Q-Pharm Pty Ltd, Herston, Queensland, Australia

KPL-301 for Subjects With Giant Cell Arteritis

Phase 2
Completed
Conditions
Giant Cell Arteritis
Interventions
Combination Product: mavrilimumab
Combination Product: placebo
First Posted Date
2019-02-01
Last Posted Date
2023-10-23
Lead Sponsor
Kiniksa Pharmaceuticals, Ltd.
Target Recruit Count
70
Registration Number
NCT03827018
Locations
🇺🇸

Site 1703, Sarasota, Florida, United States

🇺🇸

Site 1708, Tampa, Florida, United States

🇺🇸

Site 1706, Atlanta, Georgia, United States

and more 46 locations

News

Kiniksa Pharmaceuticals Advances KPL-387 Phase 2/3 Trial for Recurrent Pericarditis

Kiniksa Pharmaceuticals announced the trial design for its Phase 2/3 clinical study of KPL-387, a monoclonal antibody targeting IL-1R1, in recurrent pericarditis patients.

Kiniksa Reports Strong ARCALYST Growth, Advances KPL-387 for Recurrent Pericarditis Development

ARCALYST achieved remarkable growth with $417 million in 2024 net product revenue, representing a 79% year-over-year increase, with projected 2025 revenue between $560-580 million.

Urticaria Clinical Trial Pipeline Heats Up with Novel Therapies in Development

The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.